Multi-steroid profiling by uPLC-MS/MS with post-column infusion of ammonium

2 fluoride

- Lina Schiffer¹, Fozia Shaheen¹, Lorna C. Gilligan¹, Karl-Heinz Storbeck^{1,2}, James Hawley³,
- 4 Brian G. Keevil³, Wiebke Arlt^{1,4}, Angela E. Taylor¹
- ¹ Institute of Metabolism and Systems Research (IMSR), University of Birmingham,
- 6 Birmingham, UK
- 7 Department of Biochemistry, Stellenbosch University, Stellenbosch, South Africa
- 8 ³ Department of Clinical Biochemistry, Wythenshawe Hospital, Manchester NHS Foundation
- 9 Trust, Manchester, UK
- 10 Corresponding author: Dr Angela E Taylor, Institute of Metabolism and Systems
- 11 Research, University of Birmingham, Birmingham B15 2TT, UK. E-mail:
- 12 <u>a.taylor.5@bham.ac.uk</u>
- 13 Abstract
- 14 Background: Multi-steroid profiling is a powerful analytical tool that simultaneously
- 15 quantifies steroids from different biosynthetic pathways. Here we present an ultra-high
- 16 performance liquid chromatography-tandem mass spectrometry (uPLC-MS/MS) assay for
- 17 the profiling of 25 steroids using post-column infusion of ammonium fluoride.
- 18 **Methods:** Following liquid-liquid extraction, steroids were chromatographically separated
- 19 over 5 minutes using a Phenomenex Luna Omega C₁₈ column and a water (0.1 % formic
- 20 acid) methanol gradient. Quantification was performed on a Waters Acquity uPLC and Xevo®
- 21 TQ-XS mass spectrometer. Ammonium fluoride (6 mmol/L, post-column infusion) and formic
- acid (0.1 % (vol/vol), mobile phase additive) were compared as additives to aid ionisation.
- 23 Results: Post-column infusion (PCI) of ammonium fluoride (NH₄F) enhanced ionisation in a
- 24 steroid structure-dependent fashion compared to formic acid (122-140% for 3βOH-Δ5
- 25 steroids and 477-1274% for 3-keto-Δ4 steroids). Therefore, we fully analytically validated
- 26 PCI with NH₄F. Lower limits of quantification ranged from 0.28 to 3.42 nmol/L; 23 of 25
- 27 analytes were quantifiable with acceptable accuracy (bias range -14% to 11.9%). Average
- recovery ranged from 91.6% to 113.6% and average matrix effects from -29.9% to 19.9%.
- 29 Imprecision ranged from 2.3% to 23.9% for all analytes and was <15% for 18/25 analytes.
- The serum multi-steroid profile of 10 healthy men and 10 healthy women was measured.
- 31 Conclusions: uPLC-MS/MS with post-column infusion of ammonium fluoride enables
- 32 comprehensive multi-steroid profiling through enhanced ionisation particularly benefiting the
- 33 detection of 3-keto-Δ4 steroids.

Key words: steroid quantification, 11-oxygenated androgens, liquid chromatographytandem mass spectrometry, androgens, mineralocorticoids, glucocorticoids.

Highlights (3-5; 85 max. characters)

- This multi-steroid profiling assay quantifies 25 steroids in 5.5 minutes
- Post-column infusion of NH₄F enhances the ionisation of 3-keto-Δ4 steroids
- The assay simultaneously quantifies steroids from several biosynthetic pathways
- We present analytical data validated for serum steroid profiling

1. Introduction

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

Steroid hormones are biosynthesised in the adrenal cortex and gonads via cascade-like, interlinked enzymatic pathways and undergo extensive metabolism with both activation and inactivation in peripheral tissues (Figure 1) leading to a complex circulating steroid metabolome [1]. Steroid flux through the different pathways can be severely dysregulated in various conditions, requiring comprehensive steroid assessment to develop a mechanistic understanding of the condition and for diagnosis and treatment monitoring. Disorders of steroidogenesis with distinct steroid metabolome profiles include inborn enzymatic deficiencies such as congenital adrenal hyperplasia, autonomous adrenal steroid production such as Cushing syndrome or primary aldosteronism [2], adrenocortical carcinoma [3, 4], polycystic ovary syndrome and idiopathic intracranial hypertension [5-7]. Steroid-dependent cancers, such as prostate cancer, can locally activate steroids and are treated with various pharmacological or surgical approaches to deplete the relevant steroids and their precursors in circulation [8]. Traditionally, individual steroids have been used for the assessment of a suspected underlying condition (e.g. testosterone (T) for female androgen excess [9]; 17αhydroxyprogesterone (170HP) for congenital adrenal hyperplasia [10]). Mechanistic in-vitro studies often rely on the measurement of the end products of a biosynthesis pathway only. However, the determination of a multi-steroid profile has several advantages over the use of selected individual markers. First, steroid precursor/product ratios can be calculated to identify distinct effects on individual enzymes [11] and to assess the degree of steroid precursor activation in conditions of steroid excess. For example, in serum the ratio of T to its less active precursor androstenedione (A4) and the ratio of T to the more potent androgen 5α-dihydrotestosterone (DHT) have been shown to be excellent markers for androgen excess and the associated adverse metabolic phenotype in polycystic ovary syndrome [5, 12, 13]. Secondly, multi-steroid profiling enables different pathways of steroidogenesis to be assessed simultaneously, which is essential due to the interlinked nature of steroidogenesis and the contribution of individual enzymes to several pathways (Figure 1). Thirdly, multi-steroid profiling can be used to investigate off-target effects of inhibitors of steroidogenesis. Finally, multi-steroid profiling can be combined with machine learning approaches to generate powerful, unbiased and automated diagnostic steroid metabolomics tools [3, 4]. In contrast to immunoassays, mass spectrometry allows for multiplexing of analytes and liquid chromatography for the high-throughput that is required to effectively use multi-steroid profiling in clinical and research laboratories. Steroid analysis by mass spectrometry is often limited by poor sensitivity due to low analyte concentrations in biological samples and low ionisation efficiency of the analytes. Mobile phase additives can improve the

chromatography (peak separation and shape), enhance the signal and, thereby, sensitivity. Formic (methanoic) acid and acetic acid are common additives for corticosteroids and androgen analysis in the positive ionisation mode [5, 14, 15] as they can promote the formation of protonated molecular ions (M+H)⁺. Ammonium fluoride (NH₄F) can aid the ionisation of steroids in electrospray ionisation (ESI) in negative mode [16] and hence improve the sensitivity of oestrogen measurements [17, 18]. Additionally, NH₄F has been reported to augment the ionisation of steroids using ESI in positive ion mode in a structuredependent manner, when coupled to supercritical fluid chromatography [19]. Here, we present an ultra-high performance liquid chromatography-tandem mass spectrometry (uPLC-MS/MS) assay to measure 25 steroids (Table 1) from the mineralocorticoid, glucocorticoid, androgen, alternative and 11-oxygenated steroidogenic pathways. The separation was achieved in 5 minutes using post-column infusion of NH₄F in positive ionisation mode to enhance ionisation.

2. Material and methods

88

89

90

91

92

93

94

95

96

97

98

99

100

101 102

103

104

105

106

107

108

109

110

111

112

113

119

120

121

122

123

2.1 Preparation of external standards and quality controls

Pure standards of all analytes were purchased as powders from Sigma-Aldrich (Gillingham, UK) and Steraloids (Newport, USA); for details see Supplemental Table 1. The purity of all standards was confirmed by gas chromatography-mass spectrometry. Individual stock solutions at 1 mg/mL were prepared in uPLC grade methanol (Biosolve, Dieuze, France) and stored at -80 °C. Using the stock solutions, combined calibrators for all analytes were prepared by spiking phosphate buffered saline (PBS) pH 7.4 supplemented with 0.1% (wt/vol) bovine serum albumin (BSA) (Sigma-Aldrich) yielding at least 10 different final concentrations from 0 up to 250 ng/mL (Supplemental Table 2). A combined internal standard stock solution containing 0.5 µg/mL of each internal standard was prepared in deuterated methanol (Sigma-Aldrich).

114 Quality control (QC) samples were prepared by spiking PBS 0.1% BSA from independent 1 115 mg/mL stock solutions. Four different concentrations covering the expected concentration 116 range human serum (Supplemental Table 2). Additionally, pooled human serum (Sigma-117 Aldrich) was aliquoted, stored at -80 °C and used as biological QC in each analytical run. All 118

calibrators, internal standards and QCs were stored at -20 °C.

2.2 Collection of serum samples

The collection of blood samples was approved by the authors' Institutional Review Board (Science, Technology, Engineering and Mathematics Ethical Review Committee of the University of Birmingham, ERN_17-0494). Informed, written consent was obtained from all individuals included in this study. Following venous puncture, blood was collected into gold

- top SST Vacutainers[®] (Becton, Dickinson, Wokingham, UK). Samples were spun and the
- serum removed and stored at -80 °C until analysis. The method was applied to 20 serum
- samples from healthy volunteers 10 female and 10 males (20-40 years).

2.3 Sample preparation

127

141

152

- 128 Steroids were extracted by liquid-liquid extraction. A set of calibrators, QCs and biological
- 129 QCs were prepared with each batch of samples. Sample, calibrator, or QC (200 µL) were
- transferred into a hexamethyldisilazane-treated glass tube and 10 µL of the internal standard
- mixture containing all stable isotope labelled internal standards listed in Table S1. 50 µL of
- acetonitrile (Biosolve, Dieuze, FR) was added to precipitate the proteins and the samples
- were vortexed. 1-mL of tert-butyl methyl ether (Acros Organics, Fisher Scientific UK Ltd,
- Loughborough, UK) was added to each sample and the samples were vortexed at 1000 rpm
- for 10 minutes on a multi-vortex. The samples were incubated at room temperature for at
- least 30 minutes to aid phase separation. The organic phase was subsequently transferred
- into the wells of a 2-mL square well 96-well plate (Porvair Sciences Ltd, Wrexham, UK)
- containing 700 µL glass inserts (Randox, Crumlin, UK) and dried under a nitrogen stream at
- 45 °C. The dried extract was reconstituted in 100 μL of 50% (vol/vol) uPLC grade methanol
- 140 (Biosolve) in uPLC grade water (Biosolve) prior to analysis.

2.4 Ultra-high performance liquid chromatography

- 142 Chromatography was performed on an Acquity ultra performance liquid chromatography
- system (uPLC; Waters Ltd, Wilmslow, UK) using a Phenomenex Luna Omega column, 1.6
- μm, polar C18, 100 Å, 2.1 x 50 mm; (Phenomenex, Macclesfield, UK) at 60 °C. 10 μL of the
- 145 reconstituted sample was injected. Mobile phase A consisted of uPLC grade water
- 146 (Biosolve) and mobile phase B of uPLC grade methanol (Biosolve). An optimised method
- with a linear gradient from 45% to 75% of mobile phase B was applied over five minutes at a
- 148 flow rate of 0.6 mL/min to separate the analytes followed by a 98% wash and equilibration at
- 149 starting conditions prior to the injection of the next sample. The auto sampler was
- maintained at 10 °C. To investigate ionisation 0.1% (vol/vol) formic acid (added to mobile
- phase A or both A and B) was compared to PCI of NH₄F.

2.5 Tandem mass spectrometry

- 153 The uPLC eluate was injected into a XEVO® TQ-XS mass spectrometer (Waters Ltd) using
- 154 ESI in positive ion mode. Post-column infusion 6 mmol/L NH₄F in 50% (vol/vol) was
- 155 combined using the fluidics system on the mass spectrometer under full software control.
- 156 The capillary voltage was maintained at 1.5 kV, the source temperature was 150 °C,
- desolvation temperature and gas flow were 600 °C and 1200 L/h, cone gas was 150 L/h.
- 158 MassLynx 4.2 software (Waters Ltd) was used for systems control. Qualifier and quantifier
- 159 mass transitions, cone voltages and collision energies are summarised in Table 2.

TargetLynx software was used for data processing and quantification. Peak area ratios of analyte to internal standard were plotted against the nominal concentrations of the calibrators and 1/x weighting and linear least square regression were used to produce the standard curve.

2.6 Validation

Validation was performed following protocols from published guidelines [20-22]. For each steroid, validation has been performed at different concentrations representing low, medium and high concentrations of that steroid in serum. While this method has utility for many applications, we opted to validate for a serum application. We selected serum because it is a complex mixture of steroids, proteins, salts and many other constituents. These constituents can vary between individuals and can each affect steroid extraction and ionisation efficiencies. In addition, serum contains steroids at a range of concentrations, for example low level poor ionising steroids such as DHT (<0.3 ng/mL (1 nM)) and high concentration good ionisers like cortisol (~18 to 300 ng/mL (50-800 nM)). Optimisation using such a complex matrix means adaptation of this method to other 'cleaner' bio-fluids or cell culture supernatants should be simple.

2.6.1 Recovery and matrix effects

Matrix effects and recovery were determined as previously described [23, 24]. Six different human serum samples (four male and two female) were spiked at 5 ng/mL before extraction (pre-extract) and after extraction and reconstitution (post extract). Additionally, the reconstitution solvent (50% (vol/vol) uPLC grade methanol in uPLC grade water) was spiked with the same amounts of analytes (no extract). Percentage matrix effects and recovery were calculated from the concentrations quantified in the samples:

Matrix Effects (%)

= (Concentration (post extract) - Concentration (no extract) | Concentration (no extract) x 100

Recovery (%) = $(Concentration (pre extract) | Concentration (post extract)) \times 100$

For matrix effects mean values between -15 and 15% were considered ideal and -20% and

187 20% were acceptable. For recovery mean values between 80% and 120% were defined

188 acceptable.

2.6.2 Linearity

Three calibration series were prepared by different scientists. For each analyte the ratio of analyte peak area to internal standard peak area was plotted against the nominal

- 192 concentrations of the standard as described above. Calibration curves were accepted as
- linear if the correlation coefficient of the linear regression (\mathbb{R}^2) was ≥ 0.99 .

194 **2.6.3 Lower limit of quantification**

- The lower limit of quantification (LLOQ) was defined as the lowest concentration for which 10
- replicate samples of spiked surrogate matrix could be run with a CV <20% and a bias not
- 197 greater than ±20%.

198

205

209

211

217

2.6.4 Imprecision

- 199 Pooled surrogate matrix samples spiked with all analytes at four different concentrations
- 200 (0.3, 1, 3 and 30 ng/mL) were run 10 times in the same batch to assess intra-assay
- 201 imprecision. Pooled serum samples and pooled serum samples spiked with 5 ng/mL for all
- analytes were also run 10 times in the same batch to assess intra-assay imprecision. These
- samples were extracted and run-in different batches to assess inter-assay imprecision (n
- 204 =20). A CV ≤15% was considered optimal.

2.6.5 Accuracy

- 206 10 samples of surrogate matrix were spiked individually at four different concentrations (0.3,
- 207 1, 3 and 30 ng/mL). A bias of the observed concentration and the nominal concentration
- 208 between -15% and +15% was considered optimal.

210 **3. Results**

3.1 Chromatographic separation

- 212 Analytes were separated using a linear gradient over five minutes followed by 0.5 minutes at
- 213 starting conditions for equilibration resulting in a total run time injection-to-injection of 5.5
- 214 minutes. All analytes eluted as distinct, identifiable peaks (Supplemental Figure 1). Two
- pairs of analytes co-eluted: (cortisol (m/z 363) and 11KA4 (m/z 301); 17OHP (m/z 330) and
- 17Preg (m/z 332)). No interference was observed due to the differences in m/z (Table 2).

3.2 Comparison of additives to improve ionisation

- 218 The effect of NH₄F on signal intensity was assessed in comparison to our previously
- 219 published method using 0.1% (vol/vol) formic acid as mobile phase additive in both the
- 220 methanol and water phases [5, 7]. We chose to add NH₄F by post-column infusion as
- 221 preliminary experiments with NH₄F as an additive led to increases in system pressure
- indicative of damage to the column material (data not shown). The intra-assay imprecision
- using this modification was acceptable with a mean CV of the peak area of 7.0% for all
- analytes (CV range 3.9 to 13.7%; n=60 injections of the same sample (data not shown)).
- 225 Peak areas of all analytes in serum (n=73) were compared between the assay with formic
- 226 acid in both mobile phases and the assay using post-column infusion of NH₄F. NH₄F

227 increased peak area in a structure-dependent fashion (Figure 2, Supplemental Figure 2). In 228 comparison to formic acid, NH₄F induced significant increases in the peak area of steroids 229 with 3-keto-Δ4 structure (Prog, DOC, B, Aldo, 17OHP, S, E, F, A4, 11OHA4, 11KA4, T, 230 11KT, 11OHT), with mean increases varying from 477% (17OHP) to 1274% (Aldo). NH₄F 231 had a lower impact on the peak area of the majority of A-ring reduced steroids with changes 232 varying between 100% and 381% (DHT, 5α -dione, 3α -diol, An, 5α -DHP, 3α 5 α 17HP), with 233 the exceptions of alloP (841%) and 17OHDHP (1280%). NH₄F post-column infusion had 234 only a very minor impact on the peak areas of 3β-OH-Δ5 steroids (Preg. 17Preg. DHEA). 235 Our final optimised method employed 6 mmol/L NH₄F introduced via post-column infusion at 236 a flow rate of 5 µL/min, with 0.1% (vol/vol) formic acid in the water mobile phase to limit the 237 risk of microbial contamination.

3.3 Validation of the analytical performance

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

The analytical performance of the optimised assay with post-column infusion of NH₄F and 0.1% (vol/vol) formic acid in mobile phase A was validated. Matrix effects and recovery were assessed for six different serum samples (Table 3). Mean matrix effects ranged from -19.5% to 19.9% for all analytes and were hence in the desired range from -20% to 20%, except for 5αDHP (-29.9%), 17OHDHP (-22.6%) and 3α5α17HP (-62.7%). Mean recovery ranged from 90.0% to 113.6% for all analytes except for 3α5α17HP (122.1%), which was just outside the acceptance range of 80-120%. Calibration curves were linear with an $R^2 \ge 0.99$ for all analytes (Supplemental Table 2). Lower limits of quantification ranged between 0.1 ng/mL (~0.3 nmol/L) and 0.5 ng/mL (~1.5 nmol/L) for all analytes except for 17Preg and 3α-adiol, which had a limit of quantification of 1 ng/mL (corresponding to 3.01 and 3.42 nmol/L, respectively) (Table 3). The accuracy (bias) and imprecision of the assay were assessed with spiked PBS 0.1% BSA samples at four different concentrations. The bias between the observed and nominal concentrations was calculated as a measure of accuracy and the coefficient of variation (CV) as a measure of imprecision (Table 4). Bias was within acceptable limits for the majority of analytes at all concentrations above the LLOQ ranging from -14.0 to 11.9%, with the exception of 5αDHP at 0.3 ng/mL (-21%) and 17OHPreg at 1 ng/mL (-17.0%). Imprecision was within acceptable limits for the majority of analytes at concentrations above the LLOQ ranging from 2.3 to 14.7% with the exception of An (15.2% at 0.3 ng/mL), 3α-adiol (17.8% at 1 ng/mL), 17OHPreg (16.5% at 3 ng/mL) and alloP (at all concentrations imprecision ranged from 15.1 to 20.5%). Additionally, imprecision was assessed using a pooled serum sample (Table 5). The levels in this pooled serum sample were below the limit of quantification for 11 analytes (Preg. Prog, Aldo, DOC, 5α-dione, 3α-adiol, An, 5αDHP, alloP, 17OHDHP, 3α5α17HP). For the remaining analytes the intra-assay CV ranged from 2.4 to 16.3% and the inter-assay CV from 3.5 to 16.1%. For a pooled serum sample spiked with 5 ng/mL of all analytes the intraassay CV was between 2.3% and 12.5% for all analytes. The inter-assay CV was <15% (3.2 to 14.7%) for all steroids except 17OHDHP (17.2%), 3α -adiol (23.0%), 5α -DHP (22%) and 3α 5 α 17HP (23.9%).

3.4 Serum steroid profiling in healthy volunteers

Following validation, we applied this assay to the measurement of serum samples from 10 female (aged 23-39 years) and 10 male healthy volunteers (aged 28-37 years). The highest concentrations were observed for glucocorticoids (F and E), the adrenal androgen precursor DHEA and the mineralocorticoid precursor B. As expected, men had higher levels of T and DHT than women and the levels of all other adrenal derived steroids were similar in men and women (Figure 3). Concentrations of progesterone and its metabolites $5\alpha DHP$ and alloP were below the LLOQ in men and in 8 of 10 women. 170HDHP was not detected in any of the samples (Figure 3). The levels of 17Preg quantified in the samples using our assay were notably higher than expected based on our previous reference ranges and publications by other laboratories. While our validation demonstrates that 17Preg can be measured with acceptable precision (Table 4, 5), we conclude that using the assay presented here 17Preg cannot be quantified accurately in serum.

4. Discussion

Multi-steroid profiling provides a wider insight than quantification of a single steroid marker.

A multiplexed approach has extensive utility for the diagnosis, monitoring and the development of a mechanistic understanding of steroid-associated conditions as it allows for

the integration of steroid flux across all pathways of steroid biosynthesis and metabolism [2,

25]. This has led several clinical laboratories to increase the number of analytes that are

multiplexed in a single assay [14, 26-28]. Here, we describe the development and validation

of an uPLC-MS/MS assay for the simultaneous measurement of 25 steroids from the

mineralocorticoid, glucocorticoid, and androgen pathways of steroid biosynthesis with a total

run-time of 5.5 minutes.

293 Formic acid is a standard mobile phase additive for the analysis of steroids in positive

ionisation mode as 3-keto-Δ4 steroids predominantly form protonated molecular ions [M+H]⁺.

295 However, the sensitivity achieved with formic acid as an additive can still be insufficient to

accurately quantify the low levels of certain steroids present in serum. Hence, we tested the

effect of post-column infusion of NH₄F on the signal of all 25 steroids in our assay and

established large increases in peak area for all 3-keto-Δ4 analytes in the presence of NH₄F

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

compared to formic acid, with lower impact observed on the ionisation of A-ring reduced and 3βOH-Δ5 steroids. These findings are consistent with published results on the effect of NH₄F on the ionisation of selected steroids in a supercritical fluid chromatography set up with ESI in positive mode [19]. 3-keto-Δ4 steroids predominantly form quasi molecular ions [M+H]⁺ during ESI. Parr et al. [19] speculate that the signal enhancement observed for 3-keto-Δ4 is due to the formation of [M+H]⁺ ions being aided in the presence of NH₄F, as the proton affinity of 3-keto-∆4 steroids is higher than that of ammonia. Another possible mechanism is that F ions capture potential Na+ contaminations in the mobile phases, hence preventing the formation of [M+Na]⁺ adducts. While other assays for steroid analysis by ESI in positive mode use NH₄F as mobile phase additives [18, 29], we chose to supply NH₄F by post-column infusion to allow for cost- and time efficient incorporation of the assay into lab workflows. As indicated by the system pressure increased in our own preliminary experiments with NH₄F in the mobile phase, NH₄F can have detrimental effects on column lifetime [30], which is circumvented by post-column infusion. If running different assays on the same LC-MS/MS system, post-column infusion of additives limits the variability of mobile phase compositions that are used on the system, which could reduce the time needed for equilibration, when switching between assays that require different additives. The use of the in-built fluidics system of the mass spectrometer for the post-column infusion is simple, robust, and fully automated. The analytical validation of the assay revealed that 23/25 of the analytes can be robustly quantified at typical serum concentrations, while one of the intermediates of the alternative DHT biosynthesis pathway (3α5α17HP) and the precursor steroid 17Preg can only be semiquantitatively profiled, although the clinical utility of these steroids has yet to be determined. We applied the assay to serum samples from healthy male and female volunteers thereby demonstrating the utility of the assay. To the best of our knowledge, only two LC-MS/MS assays, which analyse 20 or more steroids in serum or plasma, have been published to date [31, 32]. However, the run-times of these assays (16 minutes [31] and 8 minutes [32]) are significantly longer than that of our assay. Published assays with run-times <6 minutes cover a maximum of 16 analytes [33-36]. Additionally, while other assays focus mainly on adrenal steroids [28, 33, 37-39] or androgen panels [14, 40], our assay comprehensively covers multiple steroid classes (Figure 1). In addition to classic androgens, such as A4 and T, our assay covers the alternative pathway of DHT biosynthesis, which contributes to androgen excess in CAH [41, 42], and the 11oxygenated androgens, which have only recently been shown to have major relevance for the diagnosis and mechanistic understanding of androgen excess conditions [6, 43-45]. Here we explored the application of this method to interrogate the complex matrix of serum. With minimal adaptations this uPLC-MS/MS method can be applied to other matrices such as bio-fluids (saliva, follicular fluid, micro-dialysis fluid etc.), tissues (adipose, brain, prostate etc.), and in-vitro cell/organ culture experiments. These applications would need further validation to determine extraction recovery and matrix effects, but depending on the matrix they could conceivably provide improved accuracy and precision especially at the LLOQ. Our assay has limitations that might be considered to hamper its use in routine clinical laboratories: It uses liquid-liquid extraction, which is inexpensive, but time-consuming and labour-intense, when performed manually, and can be challenging to automate. However, the assay can be adjusted for an extraction technique with higher throughput and better potential for (semi-)automation like supported liquid extraction or C₁₈ solid phase extraction, used with satisfying results by other serum multi-steroid assays [14, 28, 39]. Moreover, postcolumn infusion as a mode of additive delivery is not available on all mass spectrometers, where this is the case external pumps can be purchased to enable post-column infusion. Finally, not all analytes in our assay have their own stable isotope-labelled internal standard, which is usually considered a prerequisite to appropriately control for matrix effects and extraction losses and to allow for accurate and precise quantification [27, 46]. At the time this assay was developed, no internal standards were commercially available for 5α-dione, 11OHT, 5αDHP, 17OHDHP or 3α5α17HP. Therefore, quantification was performed using the internal standard eluting closest to the analyte, our validation data proves this approach to be sufficient. Use of customised deuterium- or ¹³C-labelled internal standards is expensive but could improve accuracy and imprecision of these analytes.

7. Conclusions

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354 355

356 357

358

359

360

361

- uPLC-MS/MS with post-column infusion of ammonium fluoride enables the high throughput, sensitive profiling of 25 steroids. Use of NH₄F significantly increased sensitivity for most steroids. The method was analytically validated and applied to human serum.
- 362 **Acknowledgments:** The authors thank the volunteers for the donation of blood samples.
- 363 **Research funding:** Wellcome Trust (Investigator Award WT209492/Z/17/Z, to W.A.)
- 364 Academy of Medical Sciences UK (Newton Advanced Fellowship NAF004\1002, to K.H.S).

References

- 368 [1] L. Schiffer, L. Barnard, E.S. Baranowski, L.C. Gilligan, A.E. Taylor, W. Arlt, C.H.L.
- 369 Shackleton, K.H. Storbeck, Human steroid biosynthesis, metabolism and excretion are
- 370 differentially reflected by serum and urine steroid metabolomes: A comprehensive review,
- The Journal of steroid biochemistry and molecular biology, 194 (2019) 105439.
- 372 [2] K.H. Storbeck, L. Schiffer, E.S. Baranowski, V. Chortis, A. Prete, L. Barnard, L.C.
- 373 Gilligan, A.E. Taylor, J. Idkowiak, W. Arlt, C.H.L. Shackleton, Steroid Metabolome Analysis
- in Disorders of Adrenal Steroid Biosynthesis and Metabolism, Endocrine reviews, 40 (2019) 1605-1625.
- 376 [3] W. Arlt, M. Biehl, A.E. Taylor, S. Hahner, R. Libe, B.A. Hughes, P. Schneider, D.J. Smith,
- 377 H. Stiekema, N. Krone, E. Porfiri, G. Opocher, J. Bertherat, F. Mantero, B. Allolio, M.
- 378 Terzolo, P. Nightingale, C.H. Shackleton, X. Bertagna, M. Fassnacht, P.M. Stewart, Urine
- 379 steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors, The
- Journal of clinical endocrinology and metabolism, 96 (2011) 3775-3784.
- 381 [4] I. Bancos, A.E. Taylor, V. Chortis, A.J. Sitch, C. Jenkinson, C.J. Davidge-Pitts, K. Lang,
- 382 S. Tsagarakis, M. Macech, A. Riester, T. Deutschbein, I.D. Pupovac, T. Kienitz, A. Prete,
- T.G. Papathomas, L.C. Gilligan, C. Bancos, G. Reimondo, M. Haissaguerre, L. Marina, M.A.
- 384 Grytaas, A. Sajwani, K. Langton, H.E. Ivison, C.H.L. Shackleton, D. Erickson, M. Asia, S.
- Palimeri, A. Kondracka, A. Spyroglou, C.L. Ronchi, B. Simunov, D.A. Delivanis, R.P.
- 386 Sutcliffe, I. Tsirou, T. Bednarczuk, M. Reincke, S. Burger-Stritt, R.A. Feelders, L. Canu, H.R.
- 387 Haak, G. Eisenhofer, M.C. Dennedy, G.A. Ueland, M. Ivovic, A. Tabarin, M. Terzolo, M.
- 388 Quinkler, D. Kastelan, M. Fassnacht, F. Beuschlein, U. Ambroziak, D.A. Vassiliadi, M.W.
- O'Reilly, W.F. Young, Jr., M. Biehl, J.J. Deeks, W. Arlt, Urine steroid metabolomics for the
- differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test
- validation study, Lancet Diabetes Endocrinol, 8 (2020) 773-781.
- 392 [5] M.W. O'Reilly, A.E. Taylor, N.J. Crabtree, B.A. Hughes, F. Capper, R.K. Crowley, P.M.
- 393 Stewart, J.W. Tomlinson, W. Arlt, Hyperandrogenemia predicts metabolic phenotype in
- 394 polycystic ovary syndrome: the utility of serum androstenedione, The Journal of clinical
- 395 endocrinology and metabolism, 99 (2014) 1027-1036.
- 396 [6] M.W. O'Reilly, P. Kempegowda, C. Jenkinson, A.E. Taylor, J.L. Quanson, K.H. Storbeck,
- W. Arlt, 11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary
- 398 Syndrome, The Journal of clinical endocrinology and metabolism, 102 (2017) 840-848.
- 399 [7] M.W. O'Reilly, C.S. Westgate, C. Hornby, H. Botfield, A.E. Taylor, K. Markey, J.L.
- 400 Mitchell, W.J. Scotton, S.P. Mollan, A. Yiangou, C. Jenkinson, L.C. Gilligan, M. Sherlock, J.
- Gibney, J.W. Tomlinson, G.G. Lavery, D.J. Hodson, W. Arlt, A.J. Sinclair, A unique androgen
- 402 excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid
- 403 dynamics, JCI insight, 4 (2019).
- 404 [8] G. Snaterse, J.A. Visser, W. Arlt, J. Hofland, Circulating steroid hormone variations
- throughout different stages of prostate cancer, Endocrine-related cancer, 24 (2017) R403-406 r420.
- 407 [9] D. Lizneva, L. Gavrilova-Jordan, W. Walker, R. Azziz, Androgen excess: Investigations
- 408 and management, Best practice & research. Clinical obstetrics & gynaecology, 37 (2016) 98-409 118.
- 410 [10] J.W. Honour, 17-Hydroxyprogesterone in children, adolescents and adults, Annals of
- 411 clinical biochemistry, 51 (2014) 424-440.
- 412 [11] M.P. Caulfield, T. Lynn, M.E. Gottschalk, K.L. Jones, N.F. Taylor, E.M. Malunowicz,
- 413 C.H. Shackleton, R.E. Reitz, D.A. Fisher, The diagnosis of congenital adrenal hyperplasia in
- 414 the newborn by gas chromatography/mass spectrometry analysis of random urine
- specimens, The Journal of clinical endocrinology and metabolism, 87 (2002) 3682-3690.

 [12] J. Munzker, D. Hofer, C. Trummer, M. Ulbing, A. Harger, T. Pieber, L. Owen, B. Keevil,
- 417 G. Brabant, E. Lerchbaum, B. Obermayer-Pietsch, Testosterone to dihydrotestosterone ratio
- as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome,
- The Journal of clinical endocrinology and metabolism, 100 (2015) 653-660.

- 420 [13] J. Munzker, L. Lindheim, J. Adaway, C. Trummer, E. Lerchbaum, T.R. Pieber, B. Keevil,
- 421 B. Obermayer-Pietsch, High salivary testosterone-to-androstenedione ratio and adverse
- 422 metabolic phenotypes in women with polycystic ovary syndrome, Clinical endocrinology, 86 423 (2017) 567-575.
- 424 [14] J.M. Hawley, J.E. Adaway, L.J. Owen, B.G. Keevil, Development of a total serum
- 425 testosterone, androstenedione, 17-hydroxyprogesterone, 11beta-hydroxyandrostenedione
- 426 and 11-ketotestosterone LC-MS/MS assay and its application to evaluate pre-analytical
- 427 sample stability, Clinical chemistry and laboratory medicine, DOI 10.1515/cclm-2019-428 0959(2020).
- 429 [15] Y.-C. Ma, H.-Y. Kim, Determination of Steroids by Liquid Chromatography/Mass
- 430 Spectrometry, Journal of the American Society for Mass Spectrometry, 8 (1997) 1010-1020.
- 431 [16] N.S. Rannulu, R.B. Cole, Novel Fragmentation Pathways of Anionic Adducts of Steroids
- 432 Formed by Electrospray Anion Attachment Involving Regioselective Attachment,
- 433 Regiospecific Decompositions, Charge-Induced Pathways, and Ion-Dipole Complex
- 434 Intermediates, Journal of the American Society for Mass Spectrometry, 23 (2012) 1558-435
- 436 [17] L.J. Owen, F.C. Wu, B.G. Keevil, A rapid direct assay for the routine measurement of
- 437 oestradiol and oestrone by liquid chromatography tandem mass spectrometry, Annals of 438 clinical biochemistry, 51 (2014) 360-367.
- 439 [18] S.W. Blue, A.J. Winchell, A.V. Kaucher, R.A. Lieberman, C.T. Gilles, M.N. Pyra, R.
- 440 Heffron, X. Hou, R.W. Coombs, K. Nanda, N.L. Davis, A.P. Kourtis, J.T. Herbeck, J.M.
- 441 Baeten, J.R. Lingappa, D.W. Erikson, Simultaneous quantitation of multiple contraceptive
- 442 hormones in human serum by LC-MS/MS, Contraception, 97 (2018) 363-369.
- 443 [19] M.K. Parr, B. Wüst, J. Teubel, J.F. Joseph, Splitless hyphenation of SFC with MS by
- 444 APCI, APPI, and ESI exemplified by steroids as model compounds, Journal of
- 445 Chromatography B, 1091 (2018) 67-78.
- 446 [20] J.W. Honour, Development and validation of a quantitative assay based on tandem
- 447 mass spectrometry, Annals of clinical biochemistry, 48 (2011) 97-111.
- 448 [21] U.S. Department of Health and Human Services Food and Drug Administration
- 449 Analytical Procedures and Methods Validation for Drugs and Biologics Guidance for 450 Industry, DOI (2018).
- 451 [22] B.J. Linnet K, Selection and analytical evaluation of methods - with statistical
- 452 techniques., in: A.E. Burtis CA, Bruns DE (Ed.) Tietz textbook of clinical chemistry and
- 453 molecular diagnostics, Saunders, St. Louis, 2006, pp. 353-407.
- 454 [23] P.J. Taylor, Matrix effects: the Achilles heel of quantitative high-performance liquid
- 455 chromatography-electrospray-tandem mass spectrometry, Clinical biochemistry, 38 (2005) 456
- 328-334.
- 457 [24] T.M. Annesley, Ion suppression in mass spectrometry, Clinical chemistry, 49 (2003)
- 458 1041-1044.
- 459 [25] C. Shackleton, O.J. Pozo, J. Marcos, GC/MS in Recent Years Has Defined the Normal
- 460 and Clinically Disordered Steroidome: Will It Soon Be Surpassed by LC/Tandem MS in This
- 461 Role?, Journal of the Endocrine Society, 2 (2018) 974-996.
- 462 [26] N. Janzen, S. Sander, M. Terhardt, M. Peter, J. Sander, Fast and direct quantification of
- 463 adrenal steroids by tandem mass spectrometry in serum and dried blood spots, Journal of
- 464 Chromatography B, 861 (2008) 117-122.
- 465 [27] B.G. Keevil, Novel liquid chromatography tandem mass spectrometry (LC-MS/MS)
- 466 methods for measuring steroids, Best practice & research. Clinical endocrinology &
- 467 metabolism, 27 (2013) 663-674.
- 468 [28] S. Schweitzer, M. Kunz, M. Kurlbaum, J. Vey, S. Kendl, T. Deutschbein, S. Hahner, M.
- 469 Fassnacht, T. Dandekar, M. Kroiss, Plasma steroid metabolome profiling for the diagnosis of
- 470 adrenocortical carcinoma, European journal of endocrinology, 180 (2019) 117-125.
- 471 [29] C. Wright, P. O'Day, M. Alyamani, N. Sharifi, R.J. Auchus, Abiraterone acetate
- 472 treatment lowers 11-oxygenated androgens, European journal of endocrinology, 182 (2020)
- 473 413-421.

- 474 [30] J.J. Pesek, M.T. Matyska, Ammonium fluoride as a mobile phase additive in aqueous
- 475 normal phase chromatography, Journal of chromatography. A, 1401 (2015) 69-74.
- 476 [31] M.R. Hakkinen, T. Murtola, R. Voutilainen, M. Poutanen, T. Linnanen, J. Koskivuori, T.
- 477 Lakka, J. Jaaskelainen, S. Auriola, Simultaneous analysis by LC-MS/MS of 22 ketosteroids
- 478 with hydroxylamine derivatization and underivatized estradiol from human plasma, serum
- 479 and prostate tissue, Journal of pharmaceutical and biomedical analysis, 164 (2019) 642-652.
- 480 [32] Z. Wang, H. Wang, Y. Peng, F. Chen, L. Zhao, X. Li, J. Qin, Q. Li, B. Wang, B. Pan, W.
- 481 Guo, A liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based assay to
- 482 profile 20 plasma steroids in endocrine disorders, Clinical chemistry and laboratory 483
- medicine, DOI 10.1515/cclm-2019-0869(2020).
- 484 [33] G. Karvaly, K. Kovacs, K. Meszaros, I. Kocsis, A. Patocs, B. Vasarhelyi, The
- 485 comprehensive characterization of adrenocortical steroidogenesis using two-dimensional
- 486 ultra-performance liquid chromatography - electrospray ionization tandem mass
- 487 spectrometry, Journal of pharmaceutical and biomedical analysis, 153 (2018) 274-283.
- 488 [34] U. Ceglarek, L. Kortz, A. Leichtle, G.M. Fiedler, J. Kratzsch, J. Thiery, Rapid
- 489 quantification of steroid patterns in human serum by on-line solid phase extraction combined
- 490 with liquid chromatography-triple quadrupole linear ion trap mass spectrometry, Clinica
- 491 chimica acta; international journal of clinical chemistry, 401 (2009) 114-118.
- 492 [35] A. Gaudl, J. Kratzsch, Y.J. Bae, W. Kiess, J. Thiery, U. Ceglarek, Liquid
- 493 chromatography quadrupole linear ion trap mass spectrometry for quantitative steroid
- 494 hormone analysis in plasma, urine, saliva and hair, Journal of chromatography. A, 1464
- 495 (2016) 64-71.
- 496 [36] S. Matysik, G. Liebisch, Quantification of steroid hormones in human serum by liquid
- 497 chromatography-high resolution tandem mass spectrometry, Journal of chromatography. A,
- 498 1526 (2017) 112-118.
- 499 [37] D.R. Taylor, L. Ghataore, L. Couchman, R.P. Vincent, B. Whitelaw, D. Lewis, S. Diaz-
- 500 Cano, G. Galata, K.M. Schulte, S. Aylwin, N.F. Taylor, A 13-Steroid Serum Panel Based on
- 501 LC-MS/MS: Use in Detection of Adrenocortical Carcinoma, Clinical chemistry, 63 (2017)
- 502 1836-1846.
- 503 [38] A.S. Boggs, J.A. Bowden, T.M. Galligan, L.J. Guillette, Jr., J.R. Kucklick, Development
- 504 of a multi-class steroid hormone screening method using Liquid Chromatography/Tandem
- 505 Mass Spectrometry (LC-MS/MS), Analytical and bioanalytical chemistry, 408 (2016) 4179-
- 506
- 507 [39] M. Peitzsch, T. Dekkers, M. Haase, F.C. Sweep, I. Quack, G. Antoch, G. Siegert, J.W.
- 508 Lenders, J. Deinum, H.S. Willenberg, G. Eisenhofer, An LC-MS/MS method for steroid
- 509 profiling during adrenal venous sampling for investigation of primary aldosteronism, The
- 510 Journal of steroid biochemistry and molecular biology, 145 (2015) 75-84.
- 511 [40] L.J. Owen, F.C. Wu, R.M. Buttler, B.G. Keevil, A direct assay for the routine
- 512 androstenedione, measurement of testosterone, dihydrotestosterone
- 513 dehydroepiandrosterone by liquid chromatography tandem mass spectrometry, Annals of
- 514 clinical biochemistry, 53 (2016) 580-587.
- 515 [41] C. Kamrath, Z. Hochberg, M.F. Hartmann, T. Remer, S.A. Wudy, Increased activation of
- 516 the alternative "backdoor" pathway in patients with 21-hydroxylase deficiency: evidence from
- 517 urinary steroid hormone analysis, The Journal of clinical endocrinology and metabolism, 97
- 518 (2012) E367-375.
- 519 [42] N. Reisch, A.E. Taylor, E.F. Nogueira, D.J. Asby, V. Dhir, A. Berry, N. Krone, R.J.
- 520 Auchus, C.H.L. Shackleton, N.A. Hanley, W. Arlt, Alternative pathway androgen biosynthesis
- 521 and human fetal female virilization, Proc Natl Acad Sci U S A, 116 (2019) 22294-22299.
- 522 [43] A.F. Turcu, A.T. Nanba, R. Chomic, S.K. Upadhyay, T.J. Giordano, J.J. Shields, D.P.
- 523 Merke, W.E. Rainey, R.J. Auchus, Adrenal-derived 11-oxygenated 19-carbon steroids are
- 524 the dominant androgens in classic 21-hydroxylase deficiency, European journal of
- 525 endocrinology, 174 (2016) 601-609.
- 526 [44] I. Bacila, J. Adaway, J. Hawley, S. Mahdi, R. Krone, L. Patel, S. Alvi, T. Randell, E.
- 527 Gevers, M. Dattani, T. Cheetham, A. Kyriakou, L. Schiffer, F. Ryan, E. Crowne, J.H. Davies,
- 528 S.F. Ahmed, B. Keevil, N. Krone, Measurement of Salivary Adrenal-Specific Androgens as

- Biomarkers of Therapy Control in 21-Hydroxylase Deficiency, The Journal of clinical endocrinology and metabolism, 104 (2019) 6417-6429.
- [45] C. Kamrath, L. Wettstaedt, C. Boettcher, M.F. Hartmann, S.A. Wudy, Androgen excess
- is due to elevated 11-oxygenated androgens in treated children with congenital adrenal
- 533 hyperplasia, The Journal of steroid biochemistry and molecular biology, 178 (2018) 221-228.

[46] K.M. Wooding, R.J. Auchus, Mass spectrometry theory and application to adrenal diseases, Molecular and cellular endocrinology, 371 (2013) 201-207.

Tables

537

538

539

Table 1: Nomenclature of the 25 steroids analysed in this uPLC-MS/MS assay

Steroid abbreviation	Trivial name	Chemical name	Functional class		
Preg	Pregnenolone	5-pregnene-3β-ol-20-one	General steroid precursor		
Prog	Progesterone	4-pregnene-3,20-dione	Progestogen/general steroid precursor		
DOC	11-deoxycorticosterone	4-pregnene-21-ol-3,20-dione	Mineralocorticoid precursor		
В	Corticosterone	4-pregnene-11β,21-diol-3,20-dione	Mineralocorticoid precursor		
Aldo	Aldosterone	4-pregnene-11β,21-diol-3,20-dione- 18-al	Mineralocorticoid		
17Preg	17α-hydroxypregnenolone	5-pregnene-3β,17α-diol-20-one	Glucocorticoid or androgen precursor		
17OHP	17α-hydroxyprogesterone	4-pregnene-17β-ol-3,20-dione	Glucocorticoid precursor		
S	11-deoxycortisol	4-pregnene-17α,21-diol-3,20-dione	Glucocorticoid precursor		
F	Cortisol	4-pregnene-11 β ,17 α ,21-triol-3,20-dione	Glucocorticoid		
Е	Cortisone	4-pregnene-17α,21-diol-3,11,20-trione	Glucocorticoid metabolite		
DHEA	Dehydroepiandrosterone	5-androstene-3β-ol-17-one	Classic androgen precursor		
A4	Androstenedione	4-androstene-3,17-dione	Classic androgen precursor		
Т	Testosterone	4-androstene-17β-ol-3-one	Classic androgen		
DHT	5α-dihydrotestosterone	5α-androstane-17β-ol-3-one	Classic androgen		
5α-dione	5α-androstanedione	5α-androstane-3,17-dione	Classic androgen metabolite		
3α-adiol	5α-androstanediol	5α-androstane-3α,17β-diol	Classic androgen metabolite/alternative DHT pathway intermediate		

An	5α-androsterone	5α-androstane-3α-ol-17-one	Classic androgen metabolite/alternative DHT pathway intermediate
11KA4	11-ketoandrostenedione	4-androstene-3,11,17-trione	11-oxygenated androgen precursor
11KT	11-ketotestosterone	4-androstene-17β-ol-3,11-dione	11-oxygenated androgen
110HA4	11β-hydroxyandrostenedione	4-androstene-11β-ol-3,17-dione	11-oxygenated androgen precursor
110HT	11β-hydroxytestosterone	4-androstene-11β,17β-diol-3-one	11-oxygenated androgen
5αDHP	5α-dihydroprogesterone	5α-pregnane-3,20-dione	Progestogen metabolite /alternative DHT pathway intermediate
AlloP	Allopregnanolone	5α-pregnane-3α-ol-20-one	Progestogen metabolite/alternative DHT pathway intermediate
17OHDHP	17α-hydroxy-5α- dihydroprogesterone	5α-pregnane-17α-ol-3,20-dione	Progestogen metabolite/alternative DHT pathway intermediate
3α5α17ΗΡ	17α -hydroxyallopregnanolone (or 5α , 17α -hydroxypregnanolone)	5α-pregnane-3α,17α-diol-20-one	Alternative DHT pathway intermediate

Table 2: Retention times, quantifier and qualifier mass transitions, collision energies and cone voltages of target analytes and internal standards.

Analyte	Retention time (min)	Mass transition (m/z) Quantifier Qualifier	Cone voltage (V)	Collision energy (eV)
Preg	3.65	299.2 > 281.1	36 46	12
		317.1 > 281.1	16	14
Prog	3.37	315.1 > 97.1 315.1 > 109.1	20 20	20 24
DOC	2.21	331.1 >97.1	26	20
		331.1 >109.1	26	24
В	1.52	347.2 > 121.1 347.2 >97.1	20 16	24 20
Aldo	0.86	361.2> 343.2	40	16
		361.2 > 315.1	40 8	18 12
17Preg	2.42	315.2 > 297.2 297.2 > 279.2	8 4	12 14
470110	0.45	331.1 > 97.1	16	22
17OHP	2.45	331.1 > 109.1	16	26
S	1.64	347.1 > 109.1	42	26
3	1.04	347.1 > 97.1	42	22
F	1.06	363.3 > 121.1	42	22
I-	1.00	363.1 > 91.1	42	50
Е	0.96	361.1 > 163.1	46	22
L	0.96	361.1 > 121.01	46	38
DHEA	2.35	271.2 > 253.2 289.2 > 253.2	30 12	10 8
	2.03	287.2 > 109.1	26	22
A4		287.2 > 109.1 287.2 > 97.1	26 26	22 22
-	0.00	289.2 > 97.1	40	20
Т	2.26	289.2 > 109.1	40	24
DUT	0.00	291.2 > 255.1	42	14
DHT	2.80	291.2 > 159.1	42	22
5α-dione	2.63	289.2 > 253.1	40	16
	2.03	289.2 > 271.1	40	10
3α-adiol	3.21	275.2 > 257	28	10
Ju-aui0i	J.Z I	275.2 > 81	28	28
An	3.34	291.2 > 273.2 291.2 > 255.2	24 24	8 12
		301.1 >121.1	44	22
11KA4	1.06	301.1 > 121.1	44	22 22
11KT	1.01	303.1 >121	20	22
	1.21	303.1 > 259.1	20	22
110HA4	1.34	303.1 > 285.1	30	14
		303.1 > 267.1	30	16
110HT	1.48	305.2 > 269.2 305.2 > 121.1	16 16	14 20
5 DUD	4.04	317.1 > 281.1	38	12
5αDHP	4.01	317.1 > 85.1	24	14
alloP	4.33	319.1 > 301.2 319.1 > 283.2	22 22	8 14

Internal standard	Retention time (min)	Mass transition (m/z) Quantifier Qualifier	Cone voltage (V)	Collision energy (eV)
170HDHP	2.95	333.2 > 297.2 315.1 > 111	26 32	14 16
3α5α17ΗΡ	3.85	317.2 > 299.2 317.2 > 111	28 28	12 18
Preg-d2- ¹³ C2	3.64	321.1 > 303.1	28	8
Prog-d9	3.34	324.2 > 100.1	28	24
DOC-d8	2.18	339.1 > 100.1	26	24
B-d8	1.49	355.1 > 337.2	46	14
Aldo-d8	0.85	369.2 > 351.1	34	16
17Preg-d3	2.4	336.2 > 300.2	12	10
170HP-d8	2.42	339.1 > 100.1	26	24
S-d2	1.62	349.1 > 97.1	42	22
F-d4	1.06	367.2 > 121.1	28	26
E-d7	0.95	369.1 > 169.1	40	24
DHEA-d6	2.33	277.2 > 219.1	22	14
A4-d7	2.01	294.2 > 109.1	26	22
T-d3	2.25	292.2 > 97.1	46	22
DHT-d3	2.79	294.1 > 258.1	22	16
3α-adiol-d3	3.20	278.2 >150.2	20	20
An-d4	3.33	295.1 > 277.2	24	12
11K4-d10	1.04	311 > 265	46	16
11KT-d3	1.20	306.2 > 262.1	20	22
110HA4-d7	1.30	310.1 > 292.1	30	14
5αDHP-d4	3.96	323.1 > 305.1	22	8
alloP-d4	4.31	323.1 > 305.1	22	8

Table 3: Validation summary of matrix effects, recovery and lower limits of quantification for all steroids. Matrix effects and recovery were assessed at 5 ng/mL (approximately 17 nmol/L) in serum samples from six different donors. The lower limit of quantification (LLOQ) was defined as the lowest concentration that can be assessed with appropriate accuracy (bias within \pm 20%) and imprecision (CV < 20%).

Analyte	te Matrix effects (%) Recovery (%)		LLOQ	LLOQ
	mean (min-max)	mean (min-max)	(ng/mL)	(nmol/L)
Preg	19.9 (-0.4 - 43.8)	93.9 (75.3-110)	0.2	0.6
Prog	7.4 (-8.2 - 19.7)	98.9 (91.3-110)	0.1	0.3
DOC	14.4 (9.1-20.9)	113.6 (102.9-131.4)	0.2	0.5
В	13.5 (5.3-22.5)	91.3 (74.3-110.3)	0.1	0.3
Aldo	12.6 (8.7-17.5)	103.5 (92.4-111.8)	0.2	0.4
17Preg	-15.9 (-57.9-27.8)	105.5 (59.0-129.7)	1.0	3.0
170HP	-11.4 (-31.3-24.2)	94.5 (78.0-108.6)	0.2	0.6
S	4.3 (-5.0-14.4)	99.9 (88.3-107.9)	0.2	0.4
F	-19.5 (-32.5-16.7	101.7 (7.5-108.4)	0.1	0.3
E	7.1 (-4.3-19.9)	100.7 (95.7-102.8)	0.1	0.3
DHEA	-1.4 (-20.1-12.9)	105.1 (95.0-118.2)	0.2	0.7
A4	12.7 (0.3-29.0)	95.2 (85.8-112.0)	0.2	0.7
Т	0.5 (-8.3-4.9)	102.8 (97.9-106.7)	0.1	0.4
DHT	2.4 (-9.0-10.0)	102.7 (96.6-111.7)	0.1	0.3
5α-dione	19.2 (7.8-29.7)	104.6 (88.6-113.9)	0.2	0.5
3α-adiol	4.2 (-44.1-32.8)	109.1 (96.4-138.8)	1.0	3.4
An	13.0 (5.9-23.0)	98.1 (87.0-107)	0.2	0.7
11KA4	-2.6 (-25.4-33.6)	109.0 (77.3-133.9)	0.1	0.3
11KT	10.1 (4.7-16.6)	98.0 (89.3-102.1)	0.1	0.3
110HA4	-3.6 (-17.4-17.2)	105.9 (94.1-117.8)	0.1	0.3
110HT	1.7 (-6.7-6.1)	101.8 (96.5-110.2)	0.1	0.3
5αDHP	-29.9 (-49.98.4)	113.3 (80.9-184.4)	0.2	0.6
alloP	16.0 (-22.3-40.6)	91.6 (74.0-124.1)	0.2	0.6
17OHDHP	-22.6 (-32.73.0)	90.0 (73.5-101.7)	0.5	1.5
3α5α17ΗΡ	-62.7 (-77.245.4)	122.1 (69.2-154.7)	0.5	1.5

Table 4: Accuracy and intra-assay imprecision determined at four concentrations spiked into surrogate matrix (n=10). n/a, not applicable as concentration <LLOQ.

	Bias (%)			Imprecision (%)				
Concentration (ng/mL)	0.3	1	3	30	0.3	1	3	30
Preg	-9.6	-0.4	-1.4	-3.9	8.0	5.4	13.1	4.6
Prog	-6.2	1.6	1.3	-5.0	7.0	5.3	9.1	3.3
DOC	-0.7	-2.0	3.3	-0.2	7.4	7.6	11.6	6.0
В	-5.4	-6.5	-1.8	9.2	9.4	5.8	12.1	4.8
Aldo	-7.7	-2.1	0.1	0.8	7.0	5.1	9.6	5.0
17Preg	n/a	-17	3.8	-3.6	n/a	10.4	16.5	11.1
170HP	4.9	-0.2	-5.6	0.2	5.7	10.0	9.4	6.2
S	8.4	3.9	6.8	1.8	5.5	4.8	8.3	3.8
F	2.6	7.7	10.3	2.7	5.5	4.9	4.1	2.3
Е	0.7	4.7	7.2	5.0	6.7	4.5	8.2	4.3
DHEA	10.6	4.8	0.6	2.3	13.3	10.1	8.0	3.8
A4	6.1	-5.1	-0.4	-4.6	11.3	8.2	6.9	3.7
Т	-1.8	5.3	7.5	0.6	7.6	5.6	8.2	3.8
DHT	1.3	6.4	10.2	11.9	6.7	5.1	8.4	3.2
5α-dione	-2.2	2.0	3.4	-8.0	7.8	9.5	11.2	8.0
3α-adiol	n/a	4.4	-6.1	2.5	n/a	17.8	11.5	6.5
An	2.5	1.8	-0.5	-2.9	15.2	12.2	9.1	3.5
11KA4	-9.8	-5.7	-0.5	-0.9	8.3	6.1	11.2	5.3
11KT	-8.5	0.5	2.3	-1.6	10.5	4.8	11.6	2.7
11OHA4	-4.1	1.6	2.8	-1.9	6.8	5.7	7.5	3.6
11OHT	0.2	5.6	10.9	4.0	11.6	6.8	8.0	5.0
5αDHP	-21.0	-8.2	-3.4	-4.6	14.3	12.5	11.6	14.4
alloP	-14.0	-10.7	-14.0	-11.5	20.5	16.1	15.7	15.1
17OHDHP	n/a	4.3	9.1	6.6	n/a	14.7	6.5	11.6
3α5α17ΗΡ	n/a	3.5	7.5	2.0	n/a	9.4	11.0	4.8

Table 5: Intra- and inter-assay precision of a pooled serum sample and a pooled serum sample spiked with 5 ng/mL of all analytes. (n=10). n/a, not applicable as concentration below the lower limit of quantification (<LLOQ).

	Pooled serum			Pooled serum s	piked at 5 ng/mL
Analyte	Mean (ng/mL)	Inter- assay CV (%)	Intra- assay CV (%)	Inter-assay CV (%)	Intra-assay CV (%)
Preg	<lloq< td=""><td>n/a</td><td>n/a</td><td>8.2</td><td>4.9</td></lloq<>	n/a	n/a	8.2	4.9
Prog	<lloq< td=""><td>n/a</td><td>n/a</td><td>10.8</td><td>12.5</td></lloq<>	n/a	n/a	10.8	12.5
DOC	<lloq< td=""><td>n/a</td><td>n/a</td><td>5.9</td><td>2.7</td></lloq<>	n/a	n/a	5.9	2.7
В	2.3	11.2	7.3	12.5	3.7
Aldo	<lloq< td=""><td>n/a</td><td>n/a</td><td>5.6</td><td>3.7</td></lloq<>	n/a	n/a	5.6	3.7
17Preg	4.8	16.1	16.3	14.7	8.1
170HP	1.2	5.5	4.2	12.1	4.5
S	0.2	8.1	6.9	5.8	3.5
F	75.2	3.5	2.4	3.7	2.5
Е	9.7	4.2	3.4	4.5	3.1
DHEA	2.0	6.5	6.0	6.4	6.1
A4	0.6	15.3	8.0	9.8	9.0
Т	4.0	4.7	3.5	3.2	2.3
DHT	0.4	7.5	5.4	5.4	4.1
5α-dione	<lloq< td=""><td>n/a</td><td>n/a</td><td>12.8</td><td>6.1</td></lloq<>	n/a	n/a	12.8	6.1
3α-adiol	<lloq< td=""><td>n/a</td><td>n/a</td><td>23.0</td><td>10.0</td></lloq<>	n/a	n/a	23.0	10.0
An	<lloq< td=""><td>n/a</td><td>n/a</td><td>4.0</td><td>2.8</td></lloq<>	n/a	n/a	4.0	2.8
11KA4	0.2	16.0	16.2	8.0	6.0
11KT	0.1	10.1	5.9	4.7	3.0
110HA4	1.3	12.7	10.2	9.5	5.1
11OHT	0.1	14.9	8.2	5.3	3.2
5αDHP	<lloq< td=""><td>n/a</td><td>n/a</td><td>22</td><td>4.1</td></lloq<>	n/a	n/a	22	4.1
alloP	<lloq< td=""><td>n/a</td><td>n/a</td><td>8.1</td><td>6.1</td></lloq<>	n/a	n/a	8.1	6.1
17OHDHP	<lloq< td=""><td>n/a</td><td>n/a</td><td>17.2</td><td>7.0</td></lloq<>	n/a	n/a	17.2	7.0
3α5α17ΗΡ	<lloq< td=""><td>n/a</td><td>n/a</td><td>23.9</td><td>4.2</td></lloq<>	n/a	n/a	23.9	4.2

Figure legends

573

574

575

576

577

579 580

581

582

583

584

585

586

587

588

589

590

593

594

595

597

598

599

600

601602603604605

Figure 1: Pathways of adrenal steroidogenesis (A) and androgen biosynthesis (B).

General steroid precursors are shown in yellow, mineralocorticoids in green, glucocorticoids

in orange, androgens in blue. Dark shades of each colour indicate active steroids, light

shades inactive precursors. Abbreviations for steroids included in the uPLC-MS/MS assay

are shown in bold.

Figure 2: Ammonium fluoride (NH₄F) post-column infusion enhances ionisation of steroids in a structure-dependent fashion as compared to mobile phase formic acid.

The percentage increase in peak area of the quantifier transition when comparing post-

column infusion of NH₄F (6 mmol/L, 5 µL/min) to the use of 0.1% (vol/vol) formic acid in both

the methanol and water mobile phase. Bars represent the mean percentage peak area and

whiskers the relative standard deviation for serum samples from different individuals.

Samples from all individuals with detectable peaks were included (Prog, DOC, B, 17Preg,

170HP, S, F, E, DHEA, A4, T, DHT, An, 11KA4, 11KT, 110HA4, 110HT n=74; Preg n=73;

Aldo n=71; 3α-adiol n=56; 5α-DHP n=48; 17OHDHP n=39; 3α5α17HP n=18; alloP n=15; 5α-

dione n=14). The red line indicates a relative peak area of 100% (identical ionisation with

both methods). The colour of the bars indicates the functional class of each analyte; yellow,

591 general steroid precursor; light green, mineralocorticoid precursor; dark green,

592 mineralocorticoid; orange, glucocorticoid precursor; red, glucocorticoid; turquoise, androgen

precursor; dark blue, androgen; light blue, alternative DHT biosynthesis pathway

intermediate.

Figure 3: Human Serum Steroid Profiles. Serum steroid profiles in healthy volunteers,

female (red circles; n=10, age range 20-40 years) and male (blue circles, n=10, age range

30-40 years). Each symbol represents one participant; values <LLOQ are represented by

open circles and undetectable levels were not included in the visualisation. 17OHDHP was

undetectable in any of the samples.







